The present disclosure provides intermediates and processes for preparing 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one (genistein), or a pharmaceutically acceptable salt thereof, and for methods of purification and crystallization thereof.
C07D 311/36 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
The Trustees of the University of Pennsylvania (USA)
Inventor
Harvey, Adam J.
Kaytor, Michael D.
Cengel, Keith
Diffenderfer, Eric Stanton
Abstract
Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
inflammatory pulmonary diseases; pharmaceutical preparations
for preventing and treating human tissue from the harmful
effects of radiation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of inflammatory pulmonary injury and for protecting human tissue from the harmful effects of radiation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of inflammatory pulmonary diseases; pharmaceutical preparations for preventing and treating human tissue from the harmful effects of radiation.
Ann & Robert H. Lurie Children's Hospital of Chicago (USA)
Inventor
Cho, Seong H.
Kumar, Rajesh
Anderson, Brett D.
Kaytor, Michael D.
Abstract
A novel method of treating diseases characterized by high PAI-1 is presented. Administering a composition comprising a therapeutically effective amount of genistein was found to inhibit PAI-1 promotor activity and decrease PAI-1 levels to treat diseases such as asthma, which exhibit increased PAI-1 levels. Genotyping the patient can be performed prior to administration to detect a 4G/5G polymorphism as patients having a 4G genotype have better response to the genistein treatment. The composition may be comprised of a therapeutically effective amount of genistein derived naturally from soybeans or synthetically produced and optionally present in nanoparticle form.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of inflammatory pulmonary diseases; pharmaceutical preparations for preventing and treating human tissue from the harmful effects of radiation
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of inflammatory pulmonary diseases; pharmaceutical preparations for preventing and treating human tissue from the harmful effects of radiation
Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.
Methods and materials and methods for reducing organ and tissue damage associated with inflammatory and immunological disorders are provided herein. For example, this document provides methods and materials for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, allergic responses, chemical insults, radiation, tissue injury, persistent infections, or autoimmune reactions).
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
14.
GENISTEIN TREATMENT OF INFLAMMATORY PULMONARY INJURY
Materials and methods for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, including SARS-CoV-2 infection) are provided herein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 11/00 - Drugs for disorders of the respiratory system
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
The present invention is directed to solid dispersion formulations comprising genistein and one or more pharmaceutically acceptable excipients. In particular embodiments, the one or more pharmaceutically acceptable excipients include polyvinylpyrrolidone. Various techniques can be used to form the solid dispersions, including spray drying and extrusion techniques.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
18.
GENISTEIN TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS
Methods and materials and methods for reducing organ and tissue damage associated with inflammatory and immunological disorders are provided herein. For example, this document provides methods and materials for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, allergic responses, chemical insults, radiation, tissue injury, persistent infections, or autoimmune reactions).
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Methods and materials and methods for reducing organ and tissue damage associated with inflammatory and immunological disorders are provided herein. For example, this document provides methods and materials for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, allergic responses, chemical insults, radiation, tissue injury, persistent infections, or autoimmune reactions).
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is directed to solid dispersion formulations comprising genistein and one or more pharmaceutically acceptable excipients. In particular embodiments, the one or more pharmaceutically acceptable excipients include polyvinylpyrrolidone. Various techniques can be used to form the solid dispersions, including spray drying and extrusion techniques.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
21.
SOLID DISPERSION GENISTEIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
The present invention is directed to solid dispersion formulations comprising genistein and one or more pharmaceutically acceptable excipients. In particular embodiments, the one or more pharmaceutically acceptable excipients include polyvinylpyrrolidone. Various techniques can be used to form the solid dispersions, including spray drying and extrusion techniques.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.
Materials and methods for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, including SARS-CoV-2 infection) are provided herein.
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
24.
GENISTEIN TREATMENT OF INFLAMMATORY PULMONARY INJURY
Materials and methods for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, including SARS-CoV-2 infection) are provided herein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61P 11/00 - Drugs for disorders of the respiratory system
Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein. In general, the methods can include administering a nanoparticulate genistein composition to a subject identified as having been exposed or at risk of being exposed to ionizing radiation, such as proton radiation.
A treatment regimen for a patient diagnosed with intermediate to high risk prostate cancer. The regimen is a combination therapy that includes (-) fractionated radiation therapy, (-) administration of a therapeutic amount of genistein, and (-) administration of a therapeutic amount of a gonadotropin-releasing hormonal oncologic. The treatment regimen allows the gonadotropin-releasing hormonal oncologic to be administered at a reduced dosing regimen relative to the conventional androgen deprivation therapy dosing regimen for the oncologic with minimal reduction in efficacy, thereby allowing adjustments to the androgen deprivation therapy component of the treatment regimen as necessary and appropriate for alleviating the adverse side effects that accompany androgen deprivation therapy.
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
The Trustees of the University of Pennsylvania (USA)
Inventor
Harvey, Adam J.
Kaytor, Michael D.
Cengel, Keith
Diffenderfer, Eric Stanton
Abstract
Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 μM in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A treatment regimen for a patient diagnosed with intermediate to high risk prostate cancer. The regimen is a combination therapy that includes (-) fractionated radiation therapy, (-) administration of a therapeutic amount of genistein, and (-) administration of a therapeutic amount of a gonadotropin-releasing hormonal oncologic. The treatment regimen allows the gonadotropin-releasing hormonal oncologic to be administered at a reduced dosing regimen relative to the conventional androgen deprivation therapy dosing regimen for the oncologic with minimal reduction in efficacy, thereby allowing adjustments to the androgen deprivation therapy component of the treatment regimen as necessary and appropriate for alleviating the adverse side effects that accompany androgen deprivation therapy.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nanosuspension to someone effective for achieving genistein serum levels of between 1-5 μM in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
36.
Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
Mitigation of long and short-term detrimental effects of exposure to medical imaging ionizing radiation by administration of an effective amount of genistein in the form of a nanosuspension to someone within forty eight hours prior to and/or within twelve hours after exposure to medical imaging ionizing radiation.
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
41.
PREDICTING AND REDUCING COGNITIVE DECLINE BASED ON GSK-3 LEVELS
Materials and methods for predicting cognitive decline based on total or active/inactive levels of markers such as GSK-3 are provided. Materials and methods for preventing or delaying the onset of cognitive decline in individuals identified as being in need thereof also are provided.
This invention describes the materials and methods for reducing, preventing, or mitigating the effects of exposure to toxic chemical agents. More specifically, compositions containing genistein may be useful as medical chemical countemneasures against exposure to toxic chemical agents, such as phosgene, sulfur mustard gas, and phosphine gas. The method can include identifying a subject as being at risk for exposure to the toxic chemical agent and administering to the subject an effective dose of a composition comprising nanoparticulate genistein.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
43.
SUSPENSION COMPOSITIONS OF PHYSIOLOGICALLY ACTIVE PHENOLIC COMPOUNDS & METHODS OF MAKING AND USING THE SAME
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
44.
SUSPENSION COMPOSITIONS OF PHYSIOLOGICALLY ACTIVE PHENOLIC COMPOUNDS & METHODS OF MAKING AND USING THE SAME
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
46.
GENISTEIN CANCER TREATMENT REGIMEN MAXIMIZING CANCER RADIATION THERAPY BENEFITS
A treatment regimen for a patient undergoing fractionated radiation therapy for a solid tumor type cancer to attain an improvement in one or more of and an optimized balancing of cancer cell radiation sensitization, normal cell radioprotection, selective post-exposure inhibition of cancer cell recovery relative to normal cell recovery, and stabilization of body weight during radiation treatment. The regimen comprises administration of a therapeutic amount of genistein to a patient diagnosed with a solid tumor type cancer throughout an administration period that commences at least five days prior to commencement of fractionated cancer radiation therapy and extends until at least the conclusion of fractionated cancer radiation therapy.
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
49.
NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
51.
Nanoparticle isoflavone compositions and methods of making and using the same
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
The present invention is directed to isoflavone nanoparticle compositions comprising isoflavone in the form of nanoparticles and preferably a carrier. The isoflavone nanoparticle compositions are particularly useful for preparing cosmetic compositions, pharmaceutical compositions, foodstuff, food and feed additives. In the compositions comprising the isoflavone nanoparticle compositions recrystallization of the isoflavone to bigger particles is retarded.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23K 1/16 - supplemented with accessory food factors; Salt blocks
